{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:44:47Z","timestamp":1793216687476,"version":"4.5.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81400155, 81600114, 81730003"],"award-info":[{"award-number":["81400155, 81600114, 81730003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010023","name":"Natural Science Research of Jiangsu Higher Education Institutions of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010023","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018556","name":"Science and Technology Program of Suzhou","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018556","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Chimeric antigen receptor T cell (CAR-T) therapy is an effective salvage treatment in relapsed or refractory(r\/r) diffuse large B-cell lymphoma (DLBCL), but the impact of hepatitis B virus (HBV) infection has not been studied.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and results<\/jats:title><jats:p>Here, 51 patients with r\/r DLBCL receiving CAR-T therapy were enrolled and analyzed at the First Affiliated Hospital of Soochow University. The overall response rate and the complete remission rate (CR) of CAR-T therapy were 74.5% and 39.2%, respectively. With a median follow-up of 21.1 months after CAR-T, the probabilities of overall survival (OS) and progression-free survival (PFS) at 36 months were 43.4% and 28.7%, respectively. These patients were divided into three cohorts including chronic HBV infection group (n=6), resolved HBV infection group (n=25) and non-HBV infection group (n=20). Bone marrow involvement was significantly higher in the HBV infection group(<jats:italic>P<\/jats:italic>&amp;lt;0.001), other basic characteristics before CAR-T therapy were comparable. Subgroup analysis showed that HBV infection status did not affect the efficacy of CAR-T therapy in CR rate, OS or PFS, and there was no significant difference in CAR-T related toxicities between three cohorts. Only one cirrhosis patient with chronic HBV infection experienced HBV reactivation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>CAR-T therapy was effective and can be used safely in r\/r DLBCL with HBV infection under proper monitoring and antiviral prophylaxis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1200748","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T13:16:20Z","timestamp":1684934180000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed\/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center"],"prefix":"10.3389","volume":"14","author":[{"given":"Danqing","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengming","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changju","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-817601","article-title":"Genetic landscape of hepatitis b virus-associated diffuse large b-cell lymphoma","volume":"131","author":"Ren","year":"2018","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1634\/theoncologist.2019-0756","article-title":"Hepatitis b surface antigen positivity is an independent unfavorable prognostic factor in diffuse Large b-cell lymphoma in the rituximab era","volume":"25","author":"Cheng","year":"2020","journal-title":"Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.15704","article-title":"Entecavir vs lamivudine for prevention of hepatitis b virus reactivation among patients with untreated diffuse large b-cell lymphoma receiving r-CHOP chemotherapy: a randomized clinical trial","volume":"312","author":"Huang","year":"2014","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-848044","article-title":"Risk of HBV reactivation in patients with b-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy","volume":"133","author":"Kusumoto","year":"2019","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large b-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse Large b-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004907","article-title":"Entecavir prophylaxis for hepatitis b virus reactivation in patients with CAR T-cell therapy","volume":"136","author":"Cao","year":"2020","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0913-y","article-title":"Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection","volume":"34","author":"Yang","year":"2020","journal-title":"Leukemia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0936-4","article-title":"Safety and efficacy of chimeric antigen receptor (CAR)-t-cell therapy in persons with advanced b-cell cancers and hepatitis b virus-infection","volume":"34","author":"Wang","year":"2020","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/hon.2807","article-title":"Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis b virus infection","volume":"39","author":"Cui","year":"2021","journal-title":"Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000284","article-title":"Radiation priming chimeric antigen receptor T-cell therapy in Relapsed\/Refractory diffuse Large b-cell lymphoma with high tumor burden","volume":"43","author":"Qu","year":"2020","journal-title":"J Immunother"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.187285","article-title":"Diffuse large b-cell lymphoma with concurrent hepatitis b virus infection in the MabThera era: unique clinical features and worse outcomes","volume":"14","author":"Yan","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13027-018-0190-9","article-title":"Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large b-cell lymphoma","volume":"13","author":"Al-Mansour","year":"2018","journal-title":"Infect Agent Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/1471-2407-8-115","article-title":"Clinical and prognostic analysis of hepatitis b virus infection in diffuse large b-cell lymphoma","volume":"8","author":"Wang","year":"2008","journal-title":"BMC Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00878.x","article-title":"The relationship of hepatitis b virus infection and non-hodgkin\u2019s lymphoma and its impact on clinical characteristics and prognosis","volume":"79","author":"Lim","year":"2007","journal-title":"Eur J Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.685706","article-title":"HBV reactivation during the treatment of non-Hodgkin lymphoma and management strategies","volume":"11","author":"Cao","year":"2021","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2021.06.001","article-title":"[The consensus on the prophylaxis and treatment of HBV reactivation in b or plasma cell-directed CAR-T cell therapy(2021)]","volume":"42","author":"Du","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12876-017-0596-7","article-title":"Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naive chronic hepatitis b patients","volume":"17","author":"Park","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2008.11.003","article-title":"Nucleos(t)ide analogues for hepatitis b virus: strategies for long-term success","volume":"22","author":"Chien","year":"2008","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13961","article-title":"Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study","volume":"45","author":"West","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02048","article-title":"HBV-induced immune imbalance in the development of HCC","volume":"10","author":"Chen","year":"2019","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","article-title":"Mechanisms of HBV-induced hepatocellular carcinoma","volume":"64","author":"Levrero","year":"2016","journal-title":"J Hepatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1200748\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T13:16:29Z","timestamp":1684934189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1200748\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,24]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2023.1200748"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1200748","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,24]]},"article-number":"1200748"}}